Patient Support Programs
Week ending August 30, 2026
1. Self-management questions this week
Injection/administration and handling — 1 direct question, with storage embedded.
Patients asked: “How do you administer Cosentyx (prefilled pen vs syringe vs infusion), and what are the steps around taking it out of the fridge and injecting?” Answers generally directed users to the product-specific Instructions for Use and covered not shaking, checking appearance/expiry, and device differences. This is the clearest onboarding need.
Dosing schedule — 2 direct questions.
Questions covered the plaque-psoriasis loading and maintenance regimen and how Cosentyx compares with other biologic schedules. Answers commonly described weekly doses at Weeks 0–4 followed by every-four-week maintenance. However, responses varied on when maintenance begins—“starting at Week 8,” “starting at Week 5,” and “starting Week 4/after.”
Missed doses — none this week.
No literal question asked what to do after a missed or late dose.
Side-effect self-management — no direct question.
Tolerability appeared in comparison questions, including switching from another IL-17 biologic and comparing Cosentyx with Humira, but there was no practical “what should I do about…” side-effect question.
2. Where guidance is inconsistent or thin
The most actionable gap is dosing-calendar clarity. The conflicting maintenance timing could cause patients to inject too early or delay treatment. Update onboarding calendars and nurse talking points to show the prescribed regimen by indication and device, with a clear “if a dose is late or missed, contact the prescriber/support team” pathway.
Administration answers were detailed but repeatedly hedged: “Follow your exact… Instructions for Use,” because device and country details may vary. That is appropriate, but patients may still be left without a simple, device-specific checklist. The current data show 98 hedging/disclaimer tags and 29 inconsistency flags, up from 26 last week. Most flagged inconsistencies concern omission of safety context rather than missed-dose instructions, but the pattern supports standardizing practical materials.
3. Support-pathway visibility
Some answers said “ask your prescriber” or “contact your prescribing clinician,” and several referred users to the product insert. None visibly connected patients to a nurse educator, injection-training service, or PSP hotline. This leaves patients relying on AI plus generic clinician advice for hands-on questions. Our onboarding should make the human route prominent before the first dose and when a dose is late, a device is damaged, or storage/appearance is uncertain.
4. Trend across weeks
Self-management question volume is steady at 20 total questions, but dosing-specific tagging fell to 15 from 20 last week (and from 20 two weeks ago). Across the six-week series, dosing activity is variable rather than clearly rising. Inconsistency flags increased to 29 from 26, the highest recent level, warranting attention despite lower overall response volume.
5. Recommended actions
- Update onboarding dosing calendars to resolve the Week 5 versus Week 8 maintenance wording and distinguish indications/regimens.
- Create device-specific pen/syringe and storage checklists linked to injection training and the product IFU.
- Add a missed-dose support script and FAQ, since no clear path was surfaced this week even though this is a predictable patient need.
- Promote the nurse line/PSP contact at key moments: first injection, late dose, questionable storage, or device failure.
- No new side-effect campaign this week; continue monitoring, as no direct self-management question emerged.